Adventrx's formulation of vinorelbine hit with refuse to file letter from FDA
This article was originally published in Scrip
Executive Summary
Adventrx Pharmaceuticals has received a refuse to file letter from the US FDA for its NDA for its new emulsion formulation of the generic chemotherapy drug vinorelbine, ANX-530 (vinorelbine injectable emulsion), because of manufacturing concerns.